Smith & Nephew completes acquisition of CartiHeal, knee regeneration technology

Fact checked byGina Brockenbrough, MA

Key takeaways:

Smith & Nephew has completed acquisition of CartiHeal and its Agili-C knee regeneration technology.
The acquisition closed at $180 million, with an additional $150 million contingent on financial performance.

Smith & Nephew has announced the completed acquisition of CartiHeal for $180 million, with an additional $150 million contingent on future financial performance, according to a press release.

Smith & Nephew will acquire CartiHeal’s Agili-C implant technology, a knee cartilage regeneration treatment for patients with osteochondral lesions.

ACL reconstruction — Smith & Nephew has announced the completed acquisition of CartiHeal. *Image: Adobe Stock*

“With its proven superiority to current standard of care, Agili-C has the potential to transform cartilage repair outcomes,” Scott Schaffner, president of sports medicine at Smith & Nephew, said in the release. “Our expertise in regenerative therapy and leadership in knee repair gives me great confidence that this will be a significant value creator for Smith & Nephew,” he added.

Published by:

Sources/Disclosures

Collapse

Source:

Press Release

Read more

Smith & Nephew completes acquisition of CartiHeal, knee regeneration technology

Key takeaways:

Related Content